Clinical Trial Detail

NCT ID NCT02801578
Title A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.